Medicine and Dentistry
Neuroendocrine Tumor
100%
Positron Emission Tomography-Computed Tomography
74%
Neoplasm
61%
Gallium 68
55%
Radionuclide Therapy
39%
Peptide Receptor
37%
Lutetium 177
36%
Positron Emission Tomography
34%
Somatostatin Receptor
34%
Prostate Cancer
31%
Polyethylene Terephthalate
24%
Diseases
21%
Magnetic Resonance Imaging
21%
Tetraxetan
20%
Diagnosis
19%
Computer Assisted Tomography
17%
Metastatic Carcinoma
15%
Radioligand
14%
Pancreas Islet Cell Tumor
14%
Technetium-99
13%
Somatostatin Derivative
13%
Fluorine-18
13%
Radiopharmaceutical
13%
Radioactive Tracer
12%
Receptor
12%
Dosimetry
11%
Skin Defect
11%
Fluorodeoxyglucose F 18
10%
Scintigraphy
10%
Biological Marker
10%
Gastroenteropancreatic Neuroendocrine Tumor
9%
DNA Template
9%
Lymph Node Metastasis
9%
Single-Photon Emission Computed Tomography
8%
Morphology
8%
Primary Tumor
8%
Lung
8%
Biopsy Technique
8%
Castration Resistant Prostate Cancer
8%
Cancer
8%
Liver Metastasis
8%
Standardized Uptake Value
7%
Bone Metastasis
7%
Molecular Imaging
7%
Prostate Specific Membrane Antigen
7%
Radiation Therapy
7%
Oncology
7%
Nuclear Medicine
7%
Malignant Neoplasm
7%
Merkel Cell Carcinoma
6%
Keyphrases
Neuroendocrine Tumor
79%
Positron Emission Tomography-computed Tomography (PET-CT)
73%
Peptide Receptor Radionuclide Therapy
46%
Lutetium-177 (177Lu)
42%
Tumor
27%
SUVmax
21%
Somatostatin Receptor
21%
Gallium-68
18%
Pancreatic Neuroendocrine Tumors (pNETs)
16%
Prostate-specific Antigen
15%
Somatostatin Receptor PET
14%
Prostate Cancer
14%
Prostate Cancer Patients
13%
Positron Emission tomography-CT
13%
PSMA PET-CT
13%
Radioligand Therapy
13%
Radiopharmaceuticals
13%
Computed Tomography
13%
Somatostatin Analogs
12%
DOTATATE
12%
Neuroendocrine Neoplasms
12%
Single-photon Emission Computed Tomography (SPECT)
11%
Standardized Uptake Value
10%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
10%
Positron Emission Tomography
10%
Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
10%
Molecular Imaging
10%
Ga-68
10%
Metastasis
10%
Kidney
10%
Dosimetry
10%
177Lu-DOTATATE
9%
PSMA-617
9%
Synoptic Reporting
9%
Lymph Node Metastasis
9%
68Ga-PSMA
8%
Overall Survival
8%
Primary Tumor
8%
Neuroendocrine Neoplasia
8%
177Lu-DOTATOC
8%
Biophotonics
8%
Liver Metastasis
8%
Theranostics
8%
Metastasizing
7%
68Ga-DOTANOC
7%
Immunohistochemistry
7%
SSTR2A
7%
18F-fluorodeoxyglucose (18F-FDG)
7%
DOTATOC
7%
PET Imaging
6%